Amneal Enterprises, an affiliation of independent pharmaceutical businesses, has announced the formation of a multi-year and multi-product collaboration with Oculus Innovative Sciences, Inc., an innovator and developer of tissue care products based upon the Microcyn® Technology platform.
The agreement calls for AmDerma, an Amneal alliance member, to pay Oculus $500,000 as a non-refundable initial payment for an option to license Microcyn technology for the treatment of acne. It also calls for Quinnova Pharmaceuticals, another Amneal member, to pay $500,000 to Oculus, along with double-digit royalties, for the U.S. and Canadian rights to Microcyn-based dermatology atopic dermatitis hydrogel. In addition, under the agreement, Amneal will co-promote the current Rx Microcyn-based wound care products to podiatry professionals in the U.S. and Canada.
Oculus CEO, Hoji Alimi, spoke of the importance of the agreement to Oculus. “This next-generation collaboration is an important milestone for Oculus. The breadth of the resources of the Amneal Enterprises alliance members — encompassing multiple sites, nearly a thousand employees and hundreds of scientists — are complemented by their demonstrated ability to perform. In just a few short years, Amneal Pharmaceuticals, a member of the Amneal Enterprises alliance, has become the ninth largest provider of generic prescriptions in the United States as well as the fastest growing company in the highly competitive U.S. generics industry — and also looking towards the development of new drugs. Together, we can advance towards realizing what we have always believed to be the extraordinary promise of Microcyn.”
The Oculus tissue care products based upon Microcyn Technology significantly reduce the need for antibiotics while reducing infections and accelerating healing. They successfully address the need for improved solutions in multiple markets, including dermatology, oral care, cosmeceutical, wound care and others. Several have demonstrated an ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores, increasing blood flow to the wound site, and reducing both inflammation and pain while assisting in faster wound closure.
For additional information, see the company’s website at www.Oculusis.com
Let us hear your thoughts below: